Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.
- 1Department of Thoracic Surgery, The First People's Hospital of Jiande, Jiande, China.
- 2Department of Thoracic Surgery, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
- 3Department of Radiation Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province, 310009, China. [email protected].
Abstract
Background
Osimertinib is the standard first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), but outcomes remain heterogeneous. This meta-analysis evaluated baseline clinical and molecular prognostic factors associated with poorer outcomes in this setting.Methods
PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were searched through 20 May 2026. Eligible studies included patients with EGFR-mutated advanced, recurrent, or metastatic NSCLC receiving first-line osimertinib with extractable prognostic data. The primary outcome was progression-free survival or real-world progression-free survival (PFS/rwPFS); overall survival or real-world overall survival (OS/rwOS) was secondary. Hazard ratios (HRs) were pooled using random-effects models.Results
Eighteen studies involving 4,070 first-line osimertinib-treated patients were included. TP53 mutation was associated with shorter PFS/rwPFS (HR 1.65, 95% confidence interval [CI] 1.15-2.37) and worse OS/rwOS (HR 1.55, 95% CI 1.14-2.12). EGFR L858R, versus exon 19 deletion, was associated with shorter PFS/rwPFS (HR 1.62, 95% CI 1.39-1.90) and worse OS/rwOS (HR 1.63, 95% CI 1.40-1.88), with consistent estimates across sensitivity analyses. Eastern Cooperative Oncology Group performance status ≥ 2, central nervous system/brain metastasis, and liver metastasis were associated with poorer outcomes. The OS/rwOS association for liver metastasis was sensitive to alternative estimate selection. Evidence for bone metastasis and programmed death-ligand 1 expression was less robust.Conclusions
Evidence-tier assessment identified EGFR L858R, ECOG PS ≥ 2, and CNS/brain metastasis as high-certainty adverse prognostic factors. Liver metastasis was supported by moderate certainty for PFS/rwPFS but lower certainty for OS/rwOS. TP53 mutation, PD-L1 expression, and bone metastasis were lower-certainty or exploratory findings. These findings support future integrated prognostic models, but do not establish criteria for selecting intensified first-line therapy over osimertinib monotherapy.
Related
- Integrated transcriptomic and clinical analyses reveal the prognostic relevance of GPC3 and a putative ceRNA-associated relationship in gastric cancer
- Reclassifying No Specific Molecular Profile Endometrial Cancer: A Narrative Review of Molecular Heterogeneity, Prognostic Refinement, and Clinical Management
- From Germ Cell Histogenesis to Precision Risk Stratification: Prognostic and Predictive Molecular Markers in Testicular Germ Cell Tumors-A Systematic Review.
- High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
- HEPATIC ENCEPHALOPATHY IN ALCOHOL-RELATED CIRRHOSIS:A SYSTEMATIC REVIEW OF CLINICAL CHARACTERISTICS, THERAPEUTIC STRATEGIES, AND PROGNOSTIC OUTCOMES Revisão Sistemática da Incidência, Estratégias Terapêuticas e Determinantes de Desfecho
BibTeX
@article{ruan2026clinical,
title = {{Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.}},
author = {Yingding Ruan and Hongsheng Xue and Chuan Long and Wenjun Cao and Jianwei Han and Ting Zhang},
journal = {BMC cancer},
year = {2026},
month = sep,
doi = {10.1186/s12885-026-16852-z},
url = {https://europepmc.org/article/MED/42926199},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.
AU - Yingding Ruan
AU - Hongsheng Xue
AU - Chuan Long
AU - Wenjun Cao
AU - Jianwei Han
AU - Ting Zhang
PY - 2026
DA - 2026/09/01
JO - BMC cancer
DO - 10.1186/s12885-026-16852-z
UR - https://europepmc.org/article/MED/42926199
AB - Background Osimertinib is the standard first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), but outcomes remain heterogeneous. This meta-analysis evaluated baseline clinical and molecular prognostic factors associated with poorer outcomes in this setting.Methods PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were searched through 20 May 2026. Eligible studies included patients with EGFR-mutated advanced, recurrent, or metastatic NSCLC receiving first-line osimertinib with extractable prognostic data. The primary outcome was progression-free survival or real-world progression-free survival (PFS/rwPFS); overall survival or real-world overall survival (OS/rwOS) was secondary. Hazard ratios (HRs) were pooled using random-effects models.Results Eighteen studies involving 4,070 first-line osimertinib-treated patients were included. TP53 mutation was associated with shorter PFS/rwPFS (HR 1.65, 95% confidence interval [CI] 1.15-2.37) and worse OS/rwOS (HR 1.55, 95% CI 1.14-2.12). EGFR L858R, versus exon 19 deletion, was associated with shorter PFS/rwPFS (HR 1.62, 95% CI 1.39-1.90) and worse OS/rwOS (HR 1.63, 95% CI 1.40-1.88), with consistent estimates across sensitivity analyses. Eastern Cooperative Oncology Group performance status ≥ 2, central nervous system/brain metastasis, and liver metastasis were associated with poorer outcomes. The OS/rwOS association for liver metastasis was sensitive to alternative estimate selection. Evidence for bone metastasis and programmed death-ligand 1 expression was less robust.Conclusions Evidence-tier assessment identified EGFR L858R, ECOG PS ≥ 2, and CNS/brain metastasis as high-certainty adverse prognostic factors. Liver metastasis was supported by moderate certainty for PFS/rwPFS but lower certainty for OS/rwOS. TP53 mutation, PD-L1 expression, and bone metastasis were lower-certainty or exploratory findings. These findings support future integrated prognostic models, but do not establish criteria for selecting intensified first-line therapy over osimertinib monotherapy.
SN - 1471-2407
ER -